News

Company News: InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member

– Former Lundbeck Executive Brings Strong Commercial Experience and Extensive Pharmaceutical Industry Network –

InDex Pharmaceuticals today announced that Stig Løkke Pedersen has been appointed as a new member of the Board of Directors. Mr. Pedersen brings to InDex Pharmaceuticals over 25 years of longstanding life sciences industry experience in commercial operations and leadership.

Mr. Pedersen previously served as Executive Vice President of Commercial Operations at H. Lundbeck A/S. He joined Lundbeck in January 1992, being responsible for the company’s business development activities. Following a period as Managing Director of Lundbeck Netherlands, he became part of the corporate senior management in 1998. Mr. Pedersen was appointed Executive Vice President in April 2003 and held the position as EVP for Commercial Operations from 2007 until June 2011, when he resigned from his position at Lundbeck. Mr. Pedersen is a Partner at Executive Capital A/S and serves as the Chairman of the Board of Directors at Chemometec A/S and Nuevolution A/S. He is a member of the Board of Directors at MSI Methylation Sciences Inc. and a member of the Advisory Board of Atrium Partners A/S and JSB-Partners, as well as an advisor to the Lundbeck Foundation.